Steven Nichtberger net worth and biography

Steven Nichtberger Biography and Net Worth

CEO of Cabaletta Bio

Dr. Nichtberger has served as Chief Executive Officer, President, and Chairman of Cabaletta Bio since its founding in 2017. He is also a senior fellow and professor of practice at the Wharton School of the University of Pennsylvania. In 2008, his leadership as founding CEO of Tengion (2004-2011) was recognized nationally with the prestigious Ernst & Young Entrepreneur of the Year award for emerging companies. Earlier in his career, Dr. Nichtberger served as the head of global marketing for Merck and in various commercial operating roles at the company from 1995 to 2003. He has previously served as a member of the boards of directors of MainLine Health (a regional healthcare system), the Alliance for Regenerative Medicine (as a founding member), Pennsylvania Bio, (including as chairman), and Biotechnology Industry Organization. From 2008-2019 he was a member of the board of overseers for the School of Arts & Sciences at the University of Pennsylvania. Dr. Nichtberger received his M.D. from the State University of New York at Buffalo, his B.S. from The Wharton School and his B.A. from the College of Arts & Sciences, at the University of Pennsylvania. He completed internship, residency, and fellowship in the Department of Medicine and the Division of Cardiology of the Mount Sinai Medical Center in New York.

What is Steven Nichtberger's net worth?: The estimated net worth of Steven Nichtberger is at least $4.05 million as of January 21st, 2026. Nichtberger owns 1,031,483 shares of Cabaletta Bio stock worth more than $4,048,571 as of May 4th. This net worth approximation does not reflect any other investments that Nichtberger may own. Learn More about Steven Nichtberger's net worth.
How do I contact Steven Nichtberger?: The corporate mailing address for Nichtberger and other Cabaletta Bio executives is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. Cabaletta Bio can also be reached via phone at 267-759-3100 and via email at [email protected]. Learn More on Steven Nichtberger's contact information.
Has Steven Nichtberger been buying or selling shares of Cabaletta Bio?: Steven Nichtberger has not been actively trading shares of Cabaletta Bio during the past quarter. Most recently, on Wednesday, January 21st, Steven Nichtberger bought 45,000 shares of Cabaletta Bio stock. The stock was acquired at an average cost of $2.24 per share, with a total value of $100,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,031,483 shares of the company's stock, valued at $2,310,521.92. Learn More on Steven Nichtberger's trading history.
Who are Cabaletta Bio's active insiders?: Cabaletta Bio's insider roster includes Gwendolyn Binder (Insider), Gwendolyn Binder (President, Science & Technology), David Chang (Chief Medical Officer), Steve Gavel (Insider), Michael Gerard (General Counsel), Steven Nichtberger (CEO), Mark Simon (Director), and Shawn Tomasello (Director). Learn More on Cabaletta Bio's active insiders.
Are insiders buying or selling shares of Cabaletta Bio?: In the last twelve months, Cabaletta Bio insiders bought shares 7 times. They purchased a total of 127,668 shares worth more than $286,210.51. The most recent insider tranaction occured on January, 21st when insider David J Chang bought 8,800 shares worth more than $19,888.00. Insiders at Cabaletta Bio own 11.3% of the company. Learn More about insider trades at Cabaletta Bio.
Information on this page was last updated on 1/21/2026.

Steven Nichtberger Insider Trading History at Cabaletta Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2026	Buy	45,000	$2.24	$100,800.00	1,031,483
10/18/2022	Buy	141,873	$0.99	$140,454.27	978,356

Steven Nichtberger Buying and Selling Activity at Cabaletta Bio

Cabaletta Bio Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $4.02

$3.16

$4.00

50 Day Range

MA: $3.08

$2.47

$3.52

2 Week Range

Now: $4.02

$1.11

$4.00

Volume

22,299,369 shs

Average Volume

2,968,043 shs

Market Capitalization

$447.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.18